These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35493122)

  • 1. Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.
    Goyal A; Churkin A; Barash D; Cotler SJ; Shlomai A; Etzion O; Dahari H
    Open Forum Infect Dis; 2022 May; 9(5):ofac157. PubMed ID: 35493122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling based response guided therapy in subjects with recent hepatitis C infection.
    Gorstein E; Martinello M; Churkin A; Dasgupta S; Walsh K; Applegate TL; Yardeni D; Etzion O; Uprichard SL; Barash D; Cotler SJ; Matthews GV; Dahari H
    Antiviral Res; 2020 Aug; 180():104862. PubMed ID: 32592829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
    El Sherif O; Afhdal N; Curry M
    J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
    Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
    J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning for mathematical models of HCV kinetics during antiviral therapy.
    Churkin A; Kriss S; Uziel A; Goyal A; Zakh R; Cotler SJ; Etzion O; Shlomai A; Rotstein HG; Dahari H; Barash D
    Math Biosci; 2022 Jan; 343():108756. PubMed ID: 34883104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.
    Etzion O; Dahari H; Yardeni D; Issachar A; Nevo-Shor A; Cohen-Naftaly M; Ashur Y; Uprichard SL; Arbib OS; Munteanu D; Braun M; Cotler SJ; Abufreha N; Keren-Naus A; Shemer-Avni Y; Mor O; Murad J; Novack V; Shlomai A
    Sci Rep; 2020 Oct; 10(1):17820. PubMed ID: 33082372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
    J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.
    Borgia SM; Rowaiye A
    Can J Gastroenterol Hepatol; 2015 Apr; 29(3):125-9. PubMed ID: 25855874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.
    Elshimi E; Morad W; Mohamad NE
    J Sex Med; 2019 Mar; 16(3):402-409. PubMed ID: 30846113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain.
    Turnes J; Domínguez-Hernández R; Casado MÁ
    Gastroenterol Hepatol; 2017; 40(7):433-446. PubMed ID: 28645446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection.
    Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ
    J Viral Hepat; 2019 Nov; 26(11):1301-1310. PubMed ID: 31299127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of direct-acting antiviral agents on the frequency of myeloid-derived suppressor cells and natural killer cells in patients with chronic hepatitis C.
    Li Y; Zeng Y; Zeng G; Li J; Zhang X; Cai Q; Chen Y; Lin CS
    J Med Virol; 2019 Feb; 91(2):278-286. PubMed ID: 30171691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.